In patients with both ESR1 and PIK3CA mutations who have progressed on AI+CDK4/6 inhibitor, how are you deciding the treatment/sequence of next-line therapies?  

As previously stated, this clinical dilemma is under great debate, but perhaps more clinicians are considering a transition to the oral SERD elacestrant ahead of targeted PI3K inhibitor therapy. We also now have the option to prescribe capivasertib for patients whose tumors harbor an AKT pathway mut...

In recent months, there have been multiple new drug approvals for patients with metastatic HR+/HER2- breast cancer who have progressed on standard first-line therapy with an aromatase inhibitor and a CDK4/6 inhibitor. Several agents have recently entered clinical practice which requires specific act...

I am really interested to hear what others are doing in this setting. After progression on CDK 4/6 and an AI, there are several options including alpelisib + fulvestrant per SOLAR-1, capivasertib + fulvestrant per CAPItello-291, elacestrant per EMERALD.In short, in the absence of CI such as poo...

This is a question that has been popping up. The Oncology Brothers actually asked this question to Dr. @Hope S. Rugo in their Feb. 22nd podcast. She replied that "Fortunately, this combination is somewhat unusual". She also counseled caution in combining Elacestrant and Capivasertib without evi...